Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Esculapio. 2011; 7 (3): 6-10
in English | IMEMR | ID: emr-195424

ABSTRACT

Objective: to determine the relationship of C- reactive protein with essential hypertension at 1st presentation and effect of angiotensin-11 receptor blockade on micro-inflammation


Material and Methods: twenty healthy controls and forty patients of stage 1 and stage 2 essential hypertension diagnosed at their 1st presentation at outpatient department of Services Hospital Lahore was studied. Blood of all patients was checked for CRP at 1st presentation and at the end of twelve weeks. Patients were divided in two groups A and B, group A received valsartan 80 to 160 mg per day and group B received amlodipine 5 to 20 mg per day. None of the patients required additional antihypertensive therapy


Results: the mean change in hsCRP was 0.09 mg/L among those allocated to amlodipine compared with 0.08 mg/L among those allocated to valsartan. When the means of hsCRP were compared in three groups, it was found that initial hsCRP levels were high in hypertensive group and after twelve week treatment with antihypertensive medicines there was significant drop in hsCRP levels [p<0.05]. Within the groups neither amlodipine nor valsartan showed the individual benefit on each other [p>0.05], both of them were equally effective in reducing hsCRP. No relationship was observed between hsCRP change and change of blood pressure


Conclusion: it is concluded that C-reactive protein is high in hypertensive patients and adequate control of blood pressure is required to prevent the vasculature from atherosclerotic damage

SELECTION OF CITATIONS
SEARCH DETAIL